Teva Pharmaceutical Industries Limited – Product Pipeline Review

Global Markets Direct’s, ‘Teva Pharmaceutical Industries Limited – Product Pipeline Review – 2016’, provides an overview of the Teva Pharmaceutical Industries Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Teva Pharmaceutical Industries Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Teva Pharmaceutical Industries Limited

The report provides overview of Teva Pharmaceutical Industries Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Teva Pharmaceutical Industries Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Teva Pharmaceutical Industries Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Teva Pharmaceutical Industries Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Teva Pharmaceutical Industries Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Teva Pharmaceutical Industries Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Teva Pharmaceutical Industries Limited Snapshot 6

Teva Pharmaceutical Industries Limited Overview 6

Key Information 6

Key Facts 6

Teva Pharmaceutical Industries Limited - Research and Development Overview 7

Key Therapeutic Areas 7

Teva Pharmaceutical Industries Limited - Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products - Monotherapy 13

Pipeline Products - Combination Treatment Modalities 14

Pipeline Products - Partnered Products 15

Pipeline Products - Out-Licensed Products 17

Teva Pharmaceutical Industries Limited - Pipeline Products Glance 19

Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products 19

Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products 22

Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products 24

Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products 26

Teva Pharmaceutical Industries Limited - Drug Profiles 27

(fluticasone propionate + salmeterol xinafoate) 27

deutetrabenazine ER 28

hydrocodone bitartrate ER 30

laquinimod sodium 32

reslizumab 35

omacetaxine mepesuccinate 37

(acetaminophen + hydrocodone bitartarate) IR 40

armodafinil 41

beclomethasone dipropionate 43

bendamustine hydrochloride 45

fluticasone propionate 48

rasagiline mesylate 49

TEV-48125 50

funapide 51

pridopidine hydrochloride 52

TV-1380 54

(acetaminophen + oxycodone hydrochloride) IR 55

(fluticasone propionate + salmeterol xinafoate) MDI 56

CEP-37440 57

glatiramer acetate 58

SD-560 60

TEV-48107 61

TEV-90110 62

TEV-90111 63

TEV-90112 64

TEV-90113 65

TV-44664 66

atropine sulfate 67

CEP-11981 68

CEP-28122 69

CEP-33779 70

Drug for Undisclosed Indication 71

NIB-2 72

NP-201 73

NP-202 74

Recombinant Protein to Inhibit IL-17A for Psoriasis 75

Recombinant Protein to Target CD38 for Multiple Myeloma 76

SD-1077 77

Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders 78

Small Molecule to Antagonize NMDA Receptor for Undisclosed Indication 79

Small Molecule to Inhibit CGRP for Migraine 80

Small Molecules to Inhibit DAT for Sleep Disorders 81

(acetaminophen + immediate release opioid 1) 82

(acetaminophen + immediate release opioid 2) 83

AD-3 84

AD-4 85

Fixed Dose Combination 3 for HIV 86

Fixed Dose Combination 4 for HIV 87

Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders 88

Small Molecule to Inhibit PARP-1 89

Drug for Dependence 90

Drug for Parkinson's Disease 91

risperidone LAI 92

Teva Pharmaceutical Industries Limited - Pipeline Analysis 93

Teva Pharmaceutical Industries Limited - Pipeline Products by Target 93

Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration 98

Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type 99

Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action 100

Teva Pharmaceutical Industries Limited - Recent Pipeline Updates 103

Teva Pharmaceutical Industries Limited - Dormant Projects 128

Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 131

Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 131

Discontinued Pipeline Product Profiles 131

Teva Pharmaceutical Industries Limited - Company Statement 134

Teva Pharmaceutical Industries Limited - Locations And Subsidiaries 137

Head Office 137

Other Locations & Subsidiaries 137

Appendix 145

Methodology 145

Coverage 145

Secondary Research 145

Primary Research 145

Expert Panel Validation 145

Contact Us 145

Disclaimer 146

List of Tables

List of Tables

Teva Pharmaceutical Industries Limited, Key Information 10

Teva Pharmaceutical Industries Limited, Key Facts 10

Teva Pharmaceutical Industries Limited – Pipeline by Indication, 2016 13

Teva Pharmaceutical Industries Limited – Pipeline by Stage of Development, 2016 16

Teva Pharmaceutical Industries Limited – Monotherapy Products in Pipeline, 2016 17

Teva Pharmaceutical Industries Limited – Combination Treatment Modalities in Pipeline, 2016 18

Teva Pharmaceutical Industries Limited – Partnered Products in Pipeline, 2016 19

Teva Pharmaceutical Industries Limited – Partnered Products/ Combination Treatment Modalities, 2016 20

Teva Pharmaceutical Industries Limited – Out-Licensed Products in Pipeline, 2016 21

Teva Pharmaceutical Industries Limited – Out-Licensed Products/ Combination Treatment Modalities, 2016 22

Teva Pharmaceutical Industries Limited – Pre-Registration, 2016 23

Teva Pharmaceutical Industries Limited – Filing rejected/Withdrawn, 2016 24

Teva Pharmaceutical Industries Limited – Phase III, 2016 25

Teva Pharmaceutical Industries Limited – Phase II, 2016 26

Teva Pharmaceutical Industries Limited – Phase I, 2016 27

Teva Pharmaceutical Industries Limited – Preclinical, 2016 28

Teva Pharmaceutical Industries Limited – Discovery, 2016 29

Teva Pharmaceutical Industries Limited – Unknown, 2016 30

Teva Pharmaceutical Industries Limited – Pipeline by Target, 2016 97

Teva Pharmaceutical Industries Limited – Pipeline by Route of Administration, 2016 102

Teva Pharmaceutical Industries Limited – Pipeline by Molecule Type, 2016 103

Teva Pharmaceutical Industries Limited – Pipeline Products by Mechanism of Action, 2016 104

Teva Pharmaceutical Industries Limited – Recent Pipeline Updates, 2016 107

Teva Pharmaceutical Industries Limited – Dormant Developmental Projects,2016 132

Teva Pharmaceutical Industries Limited – Discontinued Pipeline Products, 2016 135

Teva Pharmaceutical Industries Limited, Other Locations 141

Teva Pharmaceutical Industries Limited, Subsidiaries 142

List of Figures

List of Figures

Teva Pharmaceutical Industries Limited – Pipeline by Top 10 Indication, 2016 12

Teva Pharmaceutical Industries Limited – Pipeline by Stage of Development, 2016 16

Teva Pharmaceutical Industries Limited – Monotherapy Products in Pipeline, 2016 17

Teva Pharmaceutical Industries Limited – Combination Treatment Modalities in Pipeline, 2016 18

Teva Pharmaceutical Industries Limited – Partnered Products in Pipeline, 2016 19

Teva Pharmaceutical Industries Limited – Out-Licensed Products in Pipeline, 2016 21

Teva Pharmaceutical Industries Limited – Pipeline by Top 10 Target, 2016 97

Teva Pharmaceutical Industries Limited – Pipeline by Route of Administration, 2016 102

Teva Pharmaceutical Industries Limited – Pipeline by Molecule Type, 2016 103

Teva Pharmaceutical Industries Limited – Pipeline Products by Top 10 Mechanism of Action, 2016 104

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports